Contemporary Anti-Ebola Drug Discovery Approaches and Platforms

Elena K. Schneider-Futschik, Daniel Hoyer, Alexander A. Khromykh, Jonathan B. Baell, Glenn A. Marsh, Mark A. Baker, Jian Li, Tony Velkov

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The Ebola virus has a grave potential to destabilize civil society as we know it. The past few deadly Ebola outbreaks were unprecedented in size: The 2014-15 Ebola West Africa outbreak saw the virus spread from the epicenter through to Guinea, Sierra Leone, Nigeria, Congo, and Liberia. The 2014-15 Ebola West Africa outbreak was associated with almost 30,000 suspected or confirmed cases and over 11,000 documented deaths. The more recent 2018 outbreak in the Democratic Republic of Congo has so far resulted in 216 suspected or confirmed cases and 139 deaths. There is a general acceptance within the World Health Organization (WHO) and the Ebola outbreak response community that future outbreaks will become increasingly more frequent and more likely to involve intercontinental transmission. The magnitude of the recent outbreaks demonstrated in dramatic fashion the shortcomings of our mass casualty disease response capabilities and lack of therapeutic modalities for supporting Ebola outbreak prevention and control. Currently, there are no approved drugs although vaccines for human Ebola virus infection are in the trial phases and some potential treatments have been field tested most recently in the Congo Ebola outbreak. Treatment is limited to pain management and supportive care to counter dehydration and lack of oxygen. This underscores the critical need for effective antiviral drugs that specifically target this deadly disease. This review examines the current approaches for the discovery of anti-Ebola small molecule or biological therapeutics, their viral targets, mode of action, and contemporary platforms, which collectively form the backbone of the anti-Ebola drug discovery pipeline.

Original languageEnglish
Pages (from-to)35-48
Number of pages14
JournalACS Infectious Diseases
Volume5
Issue number1
DOIs
Publication statusPublished - 1 Nov 2019

Keywords

  • discovery platforms
  • drug development
  • Ebola virus
  • FDA approved drugs

Cite this

Schneider-Futschik, E. K., Hoyer, D., Khromykh, A. A., Baell, J. B., Marsh, G. A., Baker, M. A., ... Velkov, T. (2019). Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. ACS Infectious Diseases, 5(1), 35-48. https://doi.org/10.1021/acsinfecdis.8b00285
Schneider-Futschik, Elena K. ; Hoyer, Daniel ; Khromykh, Alexander A. ; Baell, Jonathan B. ; Marsh, Glenn A. ; Baker, Mark A. ; Li, Jian ; Velkov, Tony. / Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. In: ACS Infectious Diseases. 2019 ; Vol. 5, No. 1. pp. 35-48.
@article{f79f7d3da60f4b6f863b3b0bab56474a,
title = "Contemporary Anti-Ebola Drug Discovery Approaches and Platforms",
abstract = "The Ebola virus has a grave potential to destabilize civil society as we know it. The past few deadly Ebola outbreaks were unprecedented in size: The 2014-15 Ebola West Africa outbreak saw the virus spread from the epicenter through to Guinea, Sierra Leone, Nigeria, Congo, and Liberia. The 2014-15 Ebola West Africa outbreak was associated with almost 30,000 suspected or confirmed cases and over 11,000 documented deaths. The more recent 2018 outbreak in the Democratic Republic of Congo has so far resulted in 216 suspected or confirmed cases and 139 deaths. There is a general acceptance within the World Health Organization (WHO) and the Ebola outbreak response community that future outbreaks will become increasingly more frequent and more likely to involve intercontinental transmission. The magnitude of the recent outbreaks demonstrated in dramatic fashion the shortcomings of our mass casualty disease response capabilities and lack of therapeutic modalities for supporting Ebola outbreak prevention and control. Currently, there are no approved drugs although vaccines for human Ebola virus infection are in the trial phases and some potential treatments have been field tested most recently in the Congo Ebola outbreak. Treatment is limited to pain management and supportive care to counter dehydration and lack of oxygen. This underscores the critical need for effective antiviral drugs that specifically target this deadly disease. This review examines the current approaches for the discovery of anti-Ebola small molecule or biological therapeutics, their viral targets, mode of action, and contemporary platforms, which collectively form the backbone of the anti-Ebola drug discovery pipeline.",
keywords = "discovery platforms, drug development, Ebola virus, FDA approved drugs",
author = "Schneider-Futschik, {Elena K.} and Daniel Hoyer and Khromykh, {Alexander A.} and Baell, {Jonathan B.} and Marsh, {Glenn A.} and Baker, {Mark A.} and Jian Li and Tony Velkov",
year = "2019",
month = "11",
day = "1",
doi = "10.1021/acsinfecdis.8b00285",
language = "English",
volume = "5",
pages = "35--48",
journal = "ACS Infectious Diseases",
issn = "2374-4235",
publisher = "American Chemical Society",
number = "1",

}

Schneider-Futschik, EK, Hoyer, D, Khromykh, AA, Baell, JB, Marsh, GA, Baker, MA, Li, J & Velkov, T 2019, 'Contemporary Anti-Ebola Drug Discovery Approaches and Platforms' ACS Infectious Diseases, vol. 5, no. 1, pp. 35-48. https://doi.org/10.1021/acsinfecdis.8b00285

Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. / Schneider-Futschik, Elena K.; Hoyer, Daniel; Khromykh, Alexander A.; Baell, Jonathan B.; Marsh, Glenn A.; Baker, Mark A.; Li, Jian; Velkov, Tony.

In: ACS Infectious Diseases, Vol. 5, No. 1, 01.11.2019, p. 35-48.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Contemporary Anti-Ebola Drug Discovery Approaches and Platforms

AU - Schneider-Futschik, Elena K.

AU - Hoyer, Daniel

AU - Khromykh, Alexander A.

AU - Baell, Jonathan B.

AU - Marsh, Glenn A.

AU - Baker, Mark A.

AU - Li, Jian

AU - Velkov, Tony

PY - 2019/11/1

Y1 - 2019/11/1

N2 - The Ebola virus has a grave potential to destabilize civil society as we know it. The past few deadly Ebola outbreaks were unprecedented in size: The 2014-15 Ebola West Africa outbreak saw the virus spread from the epicenter through to Guinea, Sierra Leone, Nigeria, Congo, and Liberia. The 2014-15 Ebola West Africa outbreak was associated with almost 30,000 suspected or confirmed cases and over 11,000 documented deaths. The more recent 2018 outbreak in the Democratic Republic of Congo has so far resulted in 216 suspected or confirmed cases and 139 deaths. There is a general acceptance within the World Health Organization (WHO) and the Ebola outbreak response community that future outbreaks will become increasingly more frequent and more likely to involve intercontinental transmission. The magnitude of the recent outbreaks demonstrated in dramatic fashion the shortcomings of our mass casualty disease response capabilities and lack of therapeutic modalities for supporting Ebola outbreak prevention and control. Currently, there are no approved drugs although vaccines for human Ebola virus infection are in the trial phases and some potential treatments have been field tested most recently in the Congo Ebola outbreak. Treatment is limited to pain management and supportive care to counter dehydration and lack of oxygen. This underscores the critical need for effective antiviral drugs that specifically target this deadly disease. This review examines the current approaches for the discovery of anti-Ebola small molecule or biological therapeutics, their viral targets, mode of action, and contemporary platforms, which collectively form the backbone of the anti-Ebola drug discovery pipeline.

AB - The Ebola virus has a grave potential to destabilize civil society as we know it. The past few deadly Ebola outbreaks were unprecedented in size: The 2014-15 Ebola West Africa outbreak saw the virus spread from the epicenter through to Guinea, Sierra Leone, Nigeria, Congo, and Liberia. The 2014-15 Ebola West Africa outbreak was associated with almost 30,000 suspected or confirmed cases and over 11,000 documented deaths. The more recent 2018 outbreak in the Democratic Republic of Congo has so far resulted in 216 suspected or confirmed cases and 139 deaths. There is a general acceptance within the World Health Organization (WHO) and the Ebola outbreak response community that future outbreaks will become increasingly more frequent and more likely to involve intercontinental transmission. The magnitude of the recent outbreaks demonstrated in dramatic fashion the shortcomings of our mass casualty disease response capabilities and lack of therapeutic modalities for supporting Ebola outbreak prevention and control. Currently, there are no approved drugs although vaccines for human Ebola virus infection are in the trial phases and some potential treatments have been field tested most recently in the Congo Ebola outbreak. Treatment is limited to pain management and supportive care to counter dehydration and lack of oxygen. This underscores the critical need for effective antiviral drugs that specifically target this deadly disease. This review examines the current approaches for the discovery of anti-Ebola small molecule or biological therapeutics, their viral targets, mode of action, and contemporary platforms, which collectively form the backbone of the anti-Ebola drug discovery pipeline.

KW - discovery platforms

KW - drug development

KW - Ebola virus

KW - FDA approved drugs

UR - http://www.scopus.com/inward/record.url?scp=85059820236&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.8b00285

DO - 10.1021/acsinfecdis.8b00285

M3 - Article

VL - 5

SP - 35

EP - 48

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2374-4235

IS - 1

ER -

Schneider-Futschik EK, Hoyer D, Khromykh AA, Baell JB, Marsh GA, Baker MA et al. Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. ACS Infectious Diseases. 2019 Nov 1;5(1):35-48. https://doi.org/10.1021/acsinfecdis.8b00285